Thomas Swift
Molecular Titans
Thomas is a functional materials specialist who has worked across multiple industries as a research scientist, technical consultant, apprentice training provider, and innovator. Working as an academic, he has carried out technical projects for over 50 SME businesses through regional support funding and bespoke technical programmes for large multinational businesses. As an academic with a specialism in Polymer Chemistry, he has joined the development of multiple patented technologies across biomedical and healthcare sciences, including the founding technologies underpinning Molecular Titans. As apprentice programme leader, he has sat on government trailblazers setting the skills agenda for industry training standards and led a team of 20 people delivering training to
over 15 companies across the UK. His focus now is back to Polymer materials, where the Molecular Titans team can both consult or develop in-house new technologies to improve healthcare standards globally.
About the Enterprise
Infectious disease detection is slow and expensive. It is difficult to get diagnostics without waiting for external laboratory testing. In the meantime, antibiotics are being used unnecessarily causing unnecessary complications.
Molecular Titans’ unique patented polymer technology (Artemis Polymers – trademark pending) can capture targeted micro-organisms. They have demonstrated its use already by incorporating it into a portable Class IIb medical device to disclose microbial keratitis at the point of use.
Molecular titans is a materials company developing smart polymers that will be the key components of many new diagnostic and biotechnology products used by other businesses.
​
Achievements
& Highlights
Business highlights
• Since BREE fellowship began our team has been further awarded Innovate UK ICURe Explore
Funding £35,000, Leeds MedTech PBIAA (£36,000) – equity free investment through the university to support prototype development and market exploration.
• International Market Research within the ICURe program (meeting stakeholders, professional bodies, trade shows, and congresses across the UK, Italy, Germany, Portugal, and India), providing key information on MVP and the regulatory roadmap ahead of us.
• Investor funding sought - nominated as a BioCap 2025 finalist in front of MedTech investors, co-founder enrolled on RSC Changemakers program to unlock Deep Tech Funding, and we have been invited to apply for Innovate UK ICURe Exploit in 2026.
• Molecular Titans Ltd was incorporated with 2 founding partners, articles of association written to set future growth plans. We set up a company's public website, social media, and commercial bank
account, registered with Companies House.
• First bootstrapping activity to raise funds - technical consulting for a local chemical company, providing our expertise on polymer science) – providing experience in receiving purchase orders,
delivering an invoice and making payments.
• Beginning a branding exercise to make us distinct from the competition. A trademark application has
been filed to protect ‘Artemis Polymers’ technology (UK00004283487) – awaiting IPO
examination feedback.
